350 related articles for article (PubMed ID: 9922153)
21. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q.
Jiang HX; Siegel JN; Gewurz H
J Immunol; 1991 Apr; 146(7):2324-30. PubMed ID: 2005402
[TBL] [Abstract][Full Text] [Related]
22. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
Butko P; Nicholson-Weller A; Wessels MR
J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
[TBL] [Abstract][Full Text] [Related]
23. Localization of ligand-binding sites on human C1q globular head region using recombinant globular head fragments and single-chain antibodies.
Kojouharova MS; Tsacheva IG; Tchorbadjieva MI; Reid KB; Kishore U
Biochim Biophys Acta; 2003 Nov; 1652(1):64-74. PubMed ID: 14580997
[TBL] [Abstract][Full Text] [Related]
24. Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven.
Schaller M; Bigler C; Danner D; Ditzel HJ; Trendelenburg M
J Immunol; 2009 Dec; 183(12):8225-31. PubMed ID: 20007586
[TBL] [Abstract][Full Text] [Related]
25. Trypanosoma carassii calreticulin binds host complement component C1q and inhibits classical complement pathway-mediated lysis.
Oladiran A; Belosevic M
Dev Comp Immunol; 2010 Apr; 34(4):396-405. PubMed ID: 19913050
[TBL] [Abstract][Full Text] [Related]
26. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes.
Gorgani NN; Parish CR; Easterbrook Smith SB; Altin JG
Biochemistry; 1997 Jun; 36(22):6653-62. PubMed ID: 9184145
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of a calreticulin-binding nuclear protein as histone (H1), an autoantigen in systemic lupus erythematosus.
Treves S; Bajocchi G; Zorzato F; Govoni M; Trotta F
Lupus; 1998; 7(7):479-87. PubMed ID: 9796851
[TBL] [Abstract][Full Text] [Related]
28. Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions.
Tacnet-Delorme P; Chevallier S; Arlaud GJ
J Immunol; 2001 Dec; 167(11):6374-81. PubMed ID: 11714802
[TBL] [Abstract][Full Text] [Related]
29. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
30. [A stable conformer of IgG, prepared by an acidic influence: study by calorimetry, binding of the C1q complement component, and monospecific anti-IgG].
Kravchuk ZI; Vlasov AP; Liakhnovich GV; Martsev SP
Biokhimiia; 1994 Oct; 59(10):1458-77. PubMed ID: 7819387
[TBL] [Abstract][Full Text] [Related]
31. Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein.
Gronemus JQ; Hair PS; Crawford KB; Nyalwidhe JO; Cunnion KM; Krishna NK
Mol Immunol; 2010; 48(1-3):305-13. PubMed ID: 20728940
[TBL] [Abstract][Full Text] [Related]
32. Anti-C1q autoantibodies specific against the globular domain of the C1qB-chain from patient with lupus nephritis inhibit C1q binding to IgG and CRP.
Radanova M; Vasilev V; Deliyska B; Kishore U; Ikonomov V; Ivanova D
Immunobiology; 2012 Jul; 217(7):684-91. PubMed ID: 22209113
[TBL] [Abstract][Full Text] [Related]
33. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition.
Païdassi H; Tacnet-Delorme P; Verneret M; Gaboriaud C; Houen G; Duus K; Ling WL; Arlaud GJ; Frachet P
J Mol Biol; 2011 Apr; 408(2):277-90. PubMed ID: 21352829
[TBL] [Abstract][Full Text] [Related]
34. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation.
Groeneveld TW; Ramwadhdoebé TH; Trouw LA; van den Ham DL; van der Borden V; Drijfhout JW; Hiemstra PS; Daha MR; Roos A
Mol Immunol; 2007 Jul; 44(14):3608-14. PubMed ID: 17448537
[TBL] [Abstract][Full Text] [Related]
35. Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide.
Roumenina LT; Popov KT; Bureeva SV; Kojouharova M; Gadjeva M; Rabheru S; Thakrar R; Kaplun A; Kishore U
Biochim Biophys Acta; 2008 Sep; 1784(9):1271-6. PubMed ID: 18513495
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of calreticulin in systemic lupus erythematosus.
Eggleton P; Reid KB; Kishore U; Sontheimer RD
Lupus; 1997; 6(7):564-71. PubMed ID: 9302659
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of complement-mediated immune hemolysis by peptides derived from the constant domain of immunoglobulin.
Kojima T; Del Carpio CA; Tajiri H; Yoshikawa K; Saga S; Yokoyama I
Transplantation; 1999 Feb; 67(4):637-8. PubMed ID: 10071042
[TBL] [Abstract][Full Text] [Related]
38. C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus.
Uwatoko S; Aotsuka S; Okawa M; Egusa Y; Yokohari R; Aizawa C; Suzuki K
Clin Exp Immunol; 1987 Jul; 69(1):98-106. PubMed ID: 3498589
[TBL] [Abstract][Full Text] [Related]
39. Surfactant protein A regulates complement activation.
Watford WT; Wright JR; Hester CG; Jiang H; Frank MM
J Immunol; 2001 Dec; 167(11):6593-600. PubMed ID: 11714829
[TBL] [Abstract][Full Text] [Related]
40. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
